FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Raises Recommendation On Adss Of Stmicroelectronics To Buy From Hold

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our rating to Buy from Hold with a higher target price of USD60 (from USD30), implying a 2026 P/E of 45x and a 2027 P/E of 28x, as we believe STM is well positioned as a diversified analog and mixed-signal semiconductor leader with strategic exposure to electrification, energy efficiency, and digitalization across automotive, industrial, and IoT end markets, particularly through its leadership in silicon carbide power devices, automotive MCUs, and MEMS sensors. For Q2 2026, management guided net revenues to ~USD3.45B (well ahead of consensus of USD3.19B) and gross margin of around 34.8%. While our long-term view remains constructive given STM's early vertical integration in SiC and design wins with key OEMs, we remain cautious in the near term due to ongoing automotive and industrial semiconductor cycle weakness, slower-than-expected OEM inventory digestion, and suboptimal fab utilization weighing on margins. We raised our 2026 EPS estimate to USD1.30 from USD1.10 and 2027's to USD2.10 from USD1.90.

Related Articles

Asia

Piccadilly Agro Industries' Consolidated Net Profit Rises in Fiscal Q4

Piccadilly Agro Industries' (NSE:PICCADIL,BOM:530305) consolidated net profit rose to 452.3 million Indian rupees in the fiscal fourth quarter ended March 31, from 398.0 million rupees a year ago.Earnings per share came in at 4.62 rupees from 4.22 rupees a year earlier, the alcoholic beverages manufacturer said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 also increased to 3.60 billion rupees from 2.72 billion rupees a year ago.

$BOM:530305$NSE:PICCADIL
Asia

Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1

Shenzhen Hepalink Pharmaceutical (HKG:9989, SHE:002399) posted net profit attributable to shareholders of 187.6 million yuan for the first quarter, up 20% from 156.6 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical firm were up over 1% in Thursday's late morning trade.Earnings per share came in at 0.1278 yuan, compared with 0.1067 yuan a year earlier.Operating revenue fell 4.6% to 1.33 billion yuan from 1.39 billion yuan in the prior-year period.

$HKG:9989$SHE:002399
Asia

Stoneweg Europe Stapled Trust Completes Sale of Polish Office Asset for EUR23 Million

Stoneweg Europe Stapled Trust (SGX:SET) completed the divestment of a Polish office asset named Riverside Park for 22.5 million euros, according to a Thursday filing with the Singapore Exchange.The divestment is part of the trust's strategy to recycle capital, with proceeds to be used to invest in logistics and data centers.

$SGX:SET